portfolio of mere Phase 2 drugs? How about a portfolio of
portfolio of mere Phase 2 drugs? How about a portfolio of successfully completed phase2 drugs with great safety profiles and with $billion+ indications.
As for Phase3 being the most expensive it won't be for Prurisol. 505 designation allows for a small trial (100-300) or maybe no p3 trial required at all.
Go back to IHUB and keep trying to convince them that Galera has the better OM drug.You know the one that is given IV with numerous side effects..LMAO@U!
2
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Direct Digital Holdings' Impressive Growth in Q1 2025 In the realm of advertising and marketing technology, Direct Digital Holdings, Inc. (Nasdaq: DRCT) stands out with its recent financial results for the first quarter of 2025. The company, known for its innovative solutions in the advertising space, has showcased remarkable growth in several business segments,...
Continue Reading
Opportunity for Investors to Initiate Legal Proceedings Investors with significant losses in their Metagenomi, Inc. holdings may find a potential path to justice through a class action lawsuit. You might be among the shareholders whose trust has been compromised. The company, Metagenomi, Inc. (NASDAQ: MGX), faces allegations of failing to disclose crucial information that...
Continue Reading
Duck Creek Technologies Hosts the Fourth Annual One Duck Creek India Inclusion Summit In a celebration of diversity and innovation, Duck Creek Technologies is set to host its Fourth Annual One Duck Creek India Inclusion Summit. This flagship event will take place over two days, focusing on fostering a culture of inclusion and community engagement. The summit stands as a...
Continue Reading
Orion Group Financial Report Overview ORION CORPORATION has successfully released its Half-Year Financial Report highlighting impressive growth in its financial metrics for the first half of 2025. This report marks a significant achievement in the company’s performance across major divisions, reflecting a robust strategy aimed at fostering ongoing development and...
Continue Reading
Leadership Transition at Virbac Virbac is experiencing a major leadership change with the resignation of Sébastien Huron as chief executive officer. The board officially recognized this shift during their recent meeting. His departure is effective as of September 27, marking the conclusion of an important chapter for the company. Financial Terms of Resignation In...
Continue Reading